Hospital
Umass Memorial Health-Harrington Hospital INC
Umass Memorial Health-Harrington Hospital INC was paid $71.31M by Medicaid between Jan 2018 and Dec 2024, across 425 billing codes. Its largest line is 99285, emergency room visit (most serious) — 11% of everything it billed.
33Billing provider infoUMASS MEMORIAL HEALTH-HARRINGTON HOSPITAL INC
SOUTHBRIDGE, MA 01550
SOUTHBRIDGE, MA 01550
33aNPI1790780047assigned 06/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$71.31M
24GClaims2,035,807
24DCodes billed425
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#19 of 66
Median peer was paid$29.11M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 321,589 | $11.47M | |
| 2019 | 315,384 | $10.24M | |
| 2020 | 264,898 | $7.95M | |
| 2021 | 323,203 | $10.42M | |
| 2022 | 318,915 | $11.85M | |
| 2023 | 266,039 | $10.50M | |
| 2024incomplete | 225,779 | $8.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 49,186 | 44,440 | $7.70M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.8% | 18,010 | 16,133 | $6.27M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 7.9% | 98,250 | 58,462 | $5.65M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.2% | 40,550 | 37,928 | $5.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 34,283 | 31,689 | $4.95M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 22,886 | 21,655 | $3.01M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 49,853 | 15,858 | $2.68M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.0% | 29,930 | 27,337 | $2.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 9,905 | 9,422 | $1.44M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 1,905 | 1,800 | $1.33M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 11,628 | 8,783 | $1.23M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.5% | 41,787 | 13,274 | $1.07M |
413 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 18,136 | $1.00M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 8,320 | $921K |
| S9485 | Crisis intervention mental health services, per diem | 1.3% | 2,186 | $918K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 24,316 | $881K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 12,409 | $757K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 6,255 | $721K |
| 97035 | <1% | 13,593 | $712K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 7,137 | $702K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 25,071 | $689K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,796 | $661K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,303 | $598K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,564 | $595K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,875 | $588K |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | <1% | 41,470 | $545K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15,256 | $525K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14,838 | $521K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 115,018 | $472K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,460 | $447K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,316 | $429K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,856 | $410K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,603 | $389K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 13,981 | $388K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 21,434 | $377K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,919 | $368K |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 2,185 | $341K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,892 | $341K |
| 97010 | <1% | 5,645 | $328K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,810 | $294K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 3,601 | $291K |
| 80053 | Comprehensive metabolic panel | <1% | 78,026 | $284K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,878 | $257K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,601 | $254K |
| 76830 | Ultrasound, transvaginal | <1% | 2,636 | $253K |
| 93971 | <1% | 1,923 | $252K | |
| 97162 | <1% | 3,767 | $238K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 27,739 | $234K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 179 | $232K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,656 | $222K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,518 | $221K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,343 | $216K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,943 | $211K |
| 76642 | <1% | 1,772 | $202K | |
| 76770 | <1% | 1,490 | $200K | |
| 93975 | <1% | 1,994 | $199K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 6,180 | $193K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 769 | $190K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 921 | $188K |
| ATP14 | <1% | 23,589 | $160K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,182 | $160K |
| 80050 | General health panel | <1% | 9,854 | $156K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 27,338 | $147K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 425 | $147K |
| 76536 | <1% | 1,349 | $147K | |
| 97602 | <1% | 1,404 | $146K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,930 | $145K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 153 | $142K |
| 84484 | <1% | 25,359 | $141K | |
| 97163 | <1% | 2,539 | $137K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 30,940 | $137K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,649 | $131K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,546 | $131K |
| 87800 | <1% | 4,039 | $129K | |
| 72100 | <1% | 3,042 | $125K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 578 | $124K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 4,343 | $124K |
| G0378 | Hospital observation service, per hour | <1% | 6,696 | $120K |
| 71250 | <1% | 2,188 | $117K | |
| 12001 | <1% | 728 | $115K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,634 | $106K |
| 81025 | <1% | 18,375 | $102K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 405 | $100K |
| 80061 | Lipid panel | <1% | 36,050 | $99K |
| 70496 | <1% | 450 | $99K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 40,444 | $96K |
| 73630 | <1% | 4,793 | $95K | |
| 95886 | <1% | 359 | $90K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,957 | $90K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,185 | $89K |
| 0002A | <1% | 3,490 | $88K | |
| 87071 | <1% | 11,238 | $85K | |
| 77080 | <1% | 1,721 | $84K | |
| 0223U | <1% | 422 | $84K | |
| 71271 | <1% | 1,950 | $83K | |
| 87400 | <1% | 5,020 | $83K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,361 | $80K |
| 0001A | <1% | 3,591 | $80K | |
| 83880 | <1% | 5,730 | $80K | |
| 83690 | <1% | 17,900 | $78K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 762 | $77K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,592 | $76K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 462 | $75K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,867 | $74K |
| 73030 | <1% | 3,340 | $74K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,984 | $71K |
| 73130 | <1% | 3,889 | $70K | |
| 80074 | <1% | 1,877 | $69K | |
| 84439 | <1% | 11,942 | $68K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,844 | $67K |
| 83605 | <1% | 10,934 | $65K | |
| 73562 | <1% | 1,976 | $64K | |
| 82607 | <1% | 7,987 | $62K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,212 | $60K |
| 82728 | <1% | 7,636 | $59K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,195 | $58K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 851 | $56K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,679 | $51K |
| 97161 | <1% | 704 | $51K | |
| 83735 | <1% | 14,784 | $49K | |
| 85610 | <1% | 26,930 | $49K | |
| 73610 | <1% | 3,487 | $48K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 223 | $47K |
| 84153 | <1% | 4,331 | $45K | |
| ATP08 | <1% | 11,741 | $45K | |
| 81003 | <1% | 30,061 | $45K | |
| 93017 | <1% | 405 | $43K | |
| 29125 | <1% | 429 | $41K | |
| 94060 | <1% | 1,003 | $41K | |
| 87186 | <1% | 8,080 | $40K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 41 | $40K |
| 86780 | <1% | 3,577 | $39K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,733 | $39K |
| 88342 | <1% | 696 | $39K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,395 | $36K |
| 86803 | <1% | 3,623 | $35K | |
| 83550 | <1% | 6,794 | $34K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,051 | $34K |
| 73110 | <1% | 2,009 | $34K | |
| 96367 | <1% | 741 | $34K | |
| 82947 | <1% | 13,817 | $33K | |
| 82746 | <1% | 4,163 | $33K | |
| 82803 | <1% | 2,886 | $32K | |
| 84702 | <1% | 2,656 | $32K | |
| 83540 | <1% | 8,700 | $32K | |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 921 | $32K |
| 81001 | <1% | 19,583 | $32K | |
| 90715 | <1% | 1,524 | $31K | |
| 85379 | <1% | 4,737 | $29K | |
| 83970 | <1% | 2,279 | $27K | |
| 87077 | <1% | 5,816 | $26K | |
| ATP03 | <1% | 6,509 | $26K | |
| 73502 | <1% | 1,245 | $25K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 72 | $24K |
| 82570 | <1% | 11,287 | $24K | |
| 73564 | <1% | 1,003 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,497 | $23K |
| 86003 | <1% | 254 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 554 | $23K |
| 76775 | <1% | 267 | $23K | |
| 87040 | <1% | 4,119 | $22K | |
| 83655 | <1% | 2,030 | $22K | |
| 86618 | <1% | 1,882 | $22K | |
| 82043 | <1% | 8,821 | $21K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 165 | $21K |
| ATP15 | <1% | 4,087 | $21K | |
| 84703 | <1% | 3,586 | $20K | |
| 74018 | <1% | 601 | $20K | |
| 72040 | <1% | 365 | $20K | |
| 97803 | <1% | 293 | $20K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 410 | $19K |
| 87070 | <1% | 2,743 | $18K | |
| 87340 | <1% | 2,283 | $18K | |
| 86140 | <1% | 5,632 | $18K | |
| 86480 | <1% | 404 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,563 | $18K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 208 | $17K |
| 87147 | <1% | 4,014 | $17K | |
| 87081 | <1% | 3,424 | $16K | |
| 82375 | <1% | 2,693 | $16K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 272 | $16K |
| 80076 | <1% | 10,328 | $16K | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 1,464 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,769 | $15K |
| 94726 | <1% | 758 | $15K | |
| 86850 | <1% | 2,505 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,095 | $14K |
| H0001 | Alcohol and/or drug assessment | <1% | 96 | $14K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 196 | $13K |
| 84403 | <1% | 703 | $13K | |
| ATP17 | <1% | 4,838 | $13K | |
| 77061 | <1% | 122 | $13K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 304 | $12K |
| 97802 | <1% | 127 | $12K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 116 | $12K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 152 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 62,787 | $11K |
| 86706 | <1% | 1,293 | $11K | |
| 85652 | <1% | 6,460 | $11K | |
| 76882 | <1% | 100 | $10K | |
| 95885 | <1% | 98 | $10K | |
| 77066 | Tomosynthesis, mammo | <1% | 297 | $10K |
| 10060 | <1% | 119 | $10K | |
| 87480 | <1% | 621 | $10K | |
| 87660 | <1% | 621 | $10K | |
| 87510 | <1% | 620 | $10K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,395 | $9K |
| 85027 | <1% | 2,402 | $9K | |
| 84466 | <1% | 1,289 | $9K | |
| 97166 | <1% | 107 | $9K | |
| 12011 | <1% | 50 | $9K | |
| ATP10 | <1% | 2,330 | $9K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,278 | $8K |
| 94727 | <1% | 583 | $8K | |
| 87088 | <1% | 1,910 | $8K | |
| 97018 | <1% | 126 | $8K | |
| 93308 | <1% | 59 | $8K | |
| 86038 | <1% | 899 | $8K | |
| 80179 | <1% | 961 | $8K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 48 | $8K |
| 88304 | <1% | 436 | $7K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 10,410 | $7K |
| 87420 | <1% | 703 | $7K | |
| 84146 | <1% | 521 | $7K | |
| 0004A | <1% | 260 | $7K | |
| 95911 | <1% | 133 | $7K | |
| 70491 | <1% | 14 | $7K | |
| 85730 | <1% | 2,118 | $7K | |
| 80164 | <1% | 1,514 | $6K | |
| 87205 | <1% | 2,418 | $6K | |
| 82550 | <1% | 4,340 | $6K | |
| 84450 | <1% | 5,124 | $6K | |
| 86900 | <1% | 2,711 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,871 | $6K |
| 84460 | <1% | 6,121 | $6K | |
| 84100 | <1% | 7,147 | $6K | |
| 86039 | <1% | 683 | $6K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 90 | $5K |
| 77062 | <1% | 50 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 200 | $5K |
| 86901 | <1% | 2,699 | $5K | |
| 73080 | <1% | 323 | $5K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 94 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,515 | $5K |
| 0031A | <1% | 155 | $5K | |
| 95910 | <1% | 148 | $5K | |
| 82565 | <1% | 4,355 | $4K | |
| 85018 | <1% | 3,842 | $4K | |
| 70498 | <1% | 414 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,794 | $4K |
| 82652 | <1% | 120 | $4K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 144 | $4K |
| 70486 | <1% | 54 | $4K | |
| ATP09 | <1% | 905 | $4K | |
| 85014 | <1% | 3,589 | $4K | |
| 93226 | <1% | 56 | $3K | |
| ATP02 | <1% | 1,485 | $3K | |
| 82150 | <1% | 679 | $3K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 209 | $3K |
| 83721 | <1% | 804 | $3K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 921 | $3K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 469 | $3K |
| 95117 | <1% | 36 | $3K | |
| 77081 | <1% | 125 | $3K | |
| ATP04 | <1% | 602 | $2K | |
| 0072A | <1% | 55 | $2K | |
| ATP07 | <1% | 804 | $2K | |
| 73221 | <1% | 12 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 82040 | <1% | 2,795 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,952 | $2K |
| 86704 | <1% | 260 | $2K | |
| 84520 | <1% | 2,988 | $2K | |
| 74021 | <1% | 91 | $2K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 4,439 | $2K |
| 99219 | <1% | 92 | $2K | |
| 64400 | <1% | 15 | $2K | |
| 81015 | <1% | 2,646 | $2K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $2K |
| 0071A | <1% | 43 | $2K | |
| 84402 | <1% | 86 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 278 | $2K |
| 88313 | <1% | 55 | $2K | |
| 0012A | <1% | 43 | $2K | |
| 80305 | <1% | 197 | $2K | |
| 73140 | <1% | 109 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,153 | $1K |
| 84550 | <1% | 1,156 | $1K | |
| 80051 | <1% | 1,263 | $1K | |
| 86334 | <1% | 137 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 925 | $1K |
| 93018 | <1% | 201 | $1K | |
| 86431 | <1% | 342 | $1K | |
| ATP11 | <1% | 935 | $1K | |
| 0011A | <1% | 61 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,561 | $1K |
| 86762 | <1% | 100 | $1K | |
| 99406 | <1% | 55 | $1K | |
| 83001 | <1% | 85 | $1K | |
| 93016 | <1% | 128 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 589 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,495 | $1K |
| 82077 | <1% | 905 | $1K | |
| 80069 | <1% | 494 | $1K | |
| 80202 | <1% | 105 | $1K | |
| 84156 | <1% | 721 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 74 | $1K |
| 84134 | <1% | 168 | $1K | |
| 0054A | <1% | 41 | $1K | |
| ATP18 | <1% | 1,061 | $1K | |
| 84165 | <1% | 148 | $988.96 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $985.27 |
| 71101 | <1% | 40 | $974.08 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 320 | $926.03 |
| 73590 | <1% | 53 | $861.06 | |
| 80143 | <1% | 610 | $792.69 | |
| 86255 | <1% | 80 | $767.71 | |
| 73090 | <1% | 55 | $743.87 | |
| 82784 | <1% | 151 | $737.88 | |
| 82310 | <1% | 1,035 | $726.59 | |
| 91300 | <1% | 3,428 | $710.65 | |
| 96376 | <1% | 3,081 | $688.63 | |
| 90686 | <1% | 32 | $685.57 | |
| 96368 | <1% | 27 | $682.95 | |
| 83013 | <1% | 14 | $675.84 | |
| 97014 | <1% | 220 | $671.58 | |
| 87521 | Neg quan hep c or qual rna | <1% | 24 | $606.37 |
| 82542 | <1% | 70 | $603.01 | |
| 82140 | <1% | 89 | $580.32 | |
| 77091 | <1% | 188 | $574.83 | |
| 86141 | <1% | 59 | $511.65 | |
| 94760 | <1% | 4,157 | $482.46 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,007 | $471.37 |
| 86308 | <1% | 129 | $461.72 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,101 | $461.01 |
| 82977 | <1% | 182 | $445.59 | |
| 86787 | <1% | 38 | $443.48 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 28 | $425.15 |
| 86200 | <1% | 39 | $405.66 | |
| 72202 | <1% | 12 | $404.11 | |
| 97597 | <1% | 279 | $403.28 | |
| 82105 | <1% | 28 | $397.90 | |
| 80178 | <1% | 189 | $397.44 | |
| 93227 | <1% | 24 | $340.53 | |
| 87181 | <1% | 99 | $280.35 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 545 | $268.77 |
| 83883 | <1% | 28 | $251.35 | |
| 86708 | <1% | 27 | $248.60 | |
| 91307 | <1% | 109 | $234.84 | |
| 85007 | <1% | 142 | $231.15 | |
| 83002 | <1% | 13 | $229.08 | |
| 87207 | <1% | 38 | $224.92 | |
| 87899 | <1% | 50 | $224.39 | |
| ATP05 | <1% | 60 | $217.62 | |
| 84155 | <1% | 154 | $217.51 | |
| 86677 | <1% | 26 | $194.61 | |
| 84481 | <1% | 12 | $175.95 | |
| 86800 | <1% | 12 | $168.36 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,891 | $158.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 146 | $155.11 |
| 86430 | <1% | 43 | $152.10 | |
| 84311 | <1% | 318 | $130.96 | |
| ATP13 | <1% | 571 | $130.68 | |
| 83010 | <1% | 14 | $128.76 | |
| 86709 | <1% | 14 | $123.24 | |
| 92567 | <1% | 12 | $122.87 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,455 | $104.96 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 22 | $101.83 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 132 | $100.80 |
| 94644 | <1% | 256 | $86.27 | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,008 | $79.91 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,355 | $78.05 |
| 82950 | <1% | 16 | $77.96 | |
| 87015 | <1% | 25 | $75.68 | |
| ATP06 | <1% | 26 | $72.72 | |
| 80185 | <1% | 16 | $68.35 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 27 | $68.09 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 249 | $68.09 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 291 | $68.09 |
| 82378 | <1% | 27 | $65.09 | |
| 87046 | <1% | 14 | $58.44 | |
| 82248 | <1% | 99 | $52.37 | |
| 91305 | <1% | 53 | $47.76 | |
| 82272 | <1% | 13 | $23.52 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,846 | $21.14 |
| 82465 | <1% | 55 | $16.27 | |
| 85048 | <1% | 20 | $9.24 | |
| 82962 | <1% | 188 | $2.07 | |
| J3490 | Unclassified drugs | 0% | 54 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 225 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,753 | $0.00 |
| G8986 | Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 14 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 51 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 129 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 93 | $0.00 |
| 80320 | 0% | 219 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 68 | $0.00 |
| 87493 | 0% | 91 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 26 | $0.00 |
| 84478 | 0% | 13 | $0.00 | |
| 99292 | 0% | 12 | $0.00 | |
| 80329 | 0% | 43 | $0.00 | |
| 91301 | 0% | 34 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 15 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 74 | $0.00 |
| 76377 | 0% | 115 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 27 | $0.00 |
| 91303 | 0% | 79 | $0.00 | |
| 36591 | 0% | 19 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 34 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 14 | $0.00 |
| 83986 | 0% | 18 | $0.00 | |
| 76376 | 0% | 643 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 561 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 39 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 46 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 411 | $0.00 |
| 64550 | 0% | 29 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 128 | $0.00 |
| 51701 | 0% | 13 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| 36592 | 0% | 17 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 23 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRONHARD, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Umass Memorial Healthalliance Clinton Hospital INC | Leominster, MA | $82.60M |
| Umass Memorial Healthalliance Clinton Hospital INC | Clinton, MA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.